Sign in

CIK 0001725160

  • Non-accelerated filer
  • Smaller reporting company

Zentalis Pharmaceuticals, Inc.

Sign in to watch
Ticker
ZNTL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
823607803
Phone
+1 858-263-4333
Business address
10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
Former names
Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
  1. 4 Open-market sale President sold 22,500 shares at an average $24.90 ($560,254)
  2. 4 Grant or award Director acquired 36,606 shares (grant or award)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Open-market sale Chief Operating Officer sold 5,000 shares at $30.00 ($150,000)
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Open-market sale Chief Operating Officer sold 5,000 shares at $30.00 ($150,000)
  8. 4 Open-market sale Chief Operating Officer sold 5,000 shares at an average $30.01 ($150,062)
  9. 4 Open-market sale Chief Operating Officer sold 25,000 shares at $30.07 ($751,653)
  10. 4 Grant or award Director acquired 24,871 shares (grant or award)
  11. 4 Grant or award Director acquired 21,817 shares (grant or award)
  12. 3 Insider Initial Statement of Ownership
  13. 4 Grant or award President acquired 111,072 shares (grant or award)
  14. 4 Derivatives Options or other derivatives
  15. 4 Open-market sale Chief Operating Officer sold 5,000 shares at an average $30.55 ($152,745)
  16. 4 Open-market sale Chief Financial Officer sold 17,080 shares at an average $50.09 ($855,522)
  17. 4 Open-market sale President & CEO sold 20,942 shares at an average $50.01 ($1,047,317)
  18. 4 Open-market sale Director sold 10,000 shares at an average $50.48 ($504,769)
  19. 4 Open-market sale Chief Operating Officer sold 10,000 shares at an average $49.07 ($490,670)
  20. 4 Open-market sale Director sold 10,000 shares at an average $41.92 ($419,241)

Page 6 of 13 · 252 filings